[go: up one dir, main page]

AU3737500A - Method of preventing the death of retinal neurons and treating ocular diseases - Google Patents

Method of preventing the death of retinal neurons and treating ocular diseases

Info

Publication number
AU3737500A
AU3737500A AU37375/00A AU3737500A AU3737500A AU 3737500 A AU3737500 A AU 3737500A AU 37375/00 A AU37375/00 A AU 37375/00A AU 3737500 A AU3737500 A AU 3737500A AU 3737500 A AU3737500 A AU 3737500A
Authority
AU
Australia
Prior art keywords
death
preventing
ocular diseases
treating ocular
retinal neurons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU37375/00A
Inventor
Napoleone Ferrara
Audrey Goddard
Austin L. Gurney
Caroline Hebert
William J. Henzel
Rhona C. Kabakoff
Robert D. Klein
Ivar J. Kljavin
Sophia S. Kuo
Monique La Fleur
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU3737500A publication Critical patent/AU3737500A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU37375/00A 1999-03-12 2000-03-10 Method of preventing the death of retinal neurons and treating ocular diseases Abandoned AU3737500A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12395799P 1999-03-12 1999-03-12
US60123957 1999-03-12
PCT/US2000/006319 WO2000053760A2 (en) 1999-03-12 2000-03-10 Method of preventing the death of retinal neurons and treating ocular diseases

Publications (1)

Publication Number Publication Date
AU3737500A true AU3737500A (en) 2000-09-28

Family

ID=22411919

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37375/00A Abandoned AU3737500A (en) 1999-03-12 2000-03-10 Method of preventing the death of retinal neurons and treating ocular diseases

Country Status (2)

Country Link
AU (1) AU3737500A (en)
WO (1) WO2000053760A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432673B1 (en) 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
WO2002079383A2 (en) * 2001-03-30 2002-10-10 Genentech, Inc. Fizz1 for metabolism regulation
WO2004071573A2 (en) * 2003-02-07 2004-08-26 The Johns Hopkins University Hypoxia induced mitogenic factor
DK2307454T3 (en) * 2008-06-25 2017-04-24 Esbatech Alcon Biomed Res Unit Stable and soluble antibodies that inhibit VEGF
EP2849774A4 (en) * 2012-05-18 2015-11-25 Otago Innovation Ltd COMBINED TREATMENTS AND COMPOSITIONS FOR WOUND HEALING

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
WO1994001124A1 (en) * 1992-07-08 1994-01-20 Celtrix Pharmaceuticals, Inc. METHOD OF TREATING OPHTHALMIC DISORDERS USING TGF-$g(b)
WO1995014772A1 (en) * 1993-11-12 1995-06-01 Kenichi Matsubara Gene signature
WO2000032221A2 (en) * 1998-12-01 2000-06-08 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
WO1999047677A2 (en) * 1998-03-17 1999-09-23 Genentech, Inc. Polypeptides homologous to vegf and bmp1
AU2562199A (en) * 1998-01-27 1999-08-09 Eli Lilly And Company Vegf related gene and protein
ES2312205T3 (en) * 1998-03-10 2009-02-16 Genentech, Inc. NEW POLYPEPTIDE AND NUCLEIC ACIDS THAT CODE IT.
CA2334075A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. Bone morphogenic protein
WO2000034474A2 (en) * 1998-12-07 2000-06-15 Zymogenetics, Inc. Growth factor homolog zvegf3

Also Published As

Publication number Publication date
WO2000053760A3 (en) 2001-01-18
WO2000053760A2 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
AU6391000A (en) Method of preventing the injury or death of retinal cells and treating ocular diseases
AU4582797A (en) Methods for treatment of retinal diseases
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
MXPA01009544A (en) Method for treating and/or preventing retinal diseases with sustained release corticosteroids.
AU7186501A (en) Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
AU2002233643A1 (en) Methods of treating diseases in association with decrease in the expression of AOP-1 gene or AOP-1 and remedies for the diseases
AU2001288251A1 (en) Methods and devices for optical stimulation of neural tissues
AU6566094A (en) Heterocyclic derivatives in the treatment of ischaemia and related diseases
FI970489A7 (en) Topical ophthalmic compositions containing doxepin derivatives and suitable for the treatment of allergic eye diseases
AU7748000A (en) Method and composition for the treatment of dermatologic diseases
AUPQ415899A0 (en) Compositions for and methods of treatment of allergic diseases
IL137429A0 (en) Methods and compsitions for treating diseases and conditions of the eye
AU3840802A (en) Methods and compositions for the treatment of diseases of the eye
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AU2001259085A1 (en) Treatment of ocular neovascularization and related diseases
NL1010351A1 (en) Esters of carotenoids for use in the prevention and treatment of eye diseases.
CA2282682A1 (en) Tazarotene and corticosteroid treatment for psoriasis
AU1794801A (en) Method for treatment and prevention of physiological shock
AU1920501A (en) The use of caspase 9 inhibitors to treat ocular neural pathology
AU3737500A (en) Method of preventing the death of retinal neurons and treating ocular diseases
ZA971607B (en) Methods of treatment of allergic diseases
HK1048439A1 (en) Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
AU6777596A (en) Treatment of human prostate disease with beta-lapachone derivatives
AU6648200A (en) Method and composition for preventing or treating adverse physiological effects associated with cardiac disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase